- Hoth Therapeutics (NASDAQ: HOTH) is using Lantern Pharmaโs (NASDAQ: LTRN) PredictBBB.ai(TM) platform to accelerate development timelines, reduce risk, and improve candidate selection.
- This technology helps determine whether or not a candidate is able to cross the blood-brain barrier or not, which is a major holdup for many drug development companies.
- Leadership at both Lantern Pharma and Hoth Therapeutics are enthusiastic about the collaboration and how it can help deliver life-changing therapies for patients.
Hoth Therapeutics (NASDAQ: HOTH), a biopharmaceutical company, recently announced that the company is using an AI-powered platform developed byย Lantern Pharma (NASDAQ: LTRN), a clinical-stage biotech company and pharma, to streamline and improve the drug development process (https://ibn.fm/VIL67).
The platform, called PredictBBB.ai(TM), is a next-gen AI tool that was designed to help determine whether a drug candidate is able to cross the blood-brain barrier. This is a common bottleneck in drug development, and Lantern Pharmaโs platform offers 94% accuracy in predicting whether or not differentโฆ
NOTE TO INVESTORS:ย The latest news and updates relating to LTRN are available in the companyโs newsroom atย https://ibn.fm/LTRN
About BioMedWire
BioMedWireย (โBMWโ) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within theย Dynamic Brand Portfolioย @ย IBNย that delivers:ย (1) access to a vast network of wire solutions viaย InvestorWireย to efficiently and effectively reach a myriad of target markets, demographics and diverse industries;ย (2) article andย editorial syndication to 5,000+ outlets;ย (3) enhancedย press release enhancementย to ensure maximum impact;ย (4)ย social media distributionย via IBN to millions of social media followers;ย and (5) a full array of tailoredย corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in todayโs market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, โBiotechโ to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visitย https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published:ย https://www.BioMedWire.com/Disclaimer
BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is powered byย IBN
